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Hierarchical cell state models, wherein a few stem-like tumor-propagating cells repopulate the
tumor after therapy, are often invoked in cancer. Suva` et al. demonstrate a plastic developmental
hierarchy in glioma cell populations by characterizing the epigenetic states of phenotypically
distinct cells and identifying four factors sufficient to reprogram differentiated cells into a tumori-
genic stem-like state.Solid tumors are heterogeneous masses
with various tumor stroma components
as well as subpopulations of bona fide
tumor cells caused by the parallel evolu-
tion of genetically distinct subclones.
This branching evolution is typically
considered as a unidirectional process,
driven by stepwise accumulation of addi-
tional genetic alterations. In contrast, the
epigenome represents a more dynamic/
multidirectional state that enables cells
to adapt to different conditions, allowing
for morphological and functional differ-
ences within genetically identical cell
populations. This functional flexibility is
of key importance for the cancer stem
cell concept, in which a small subpopula-
tion of tumor-propagating cells with stem
cell-like features spawns progeny that
undergo a transient expansion and then
‘‘pseudo-differentiation’’ to form the tu-
mor bulk (reviewed in Kreso and Dick
[2014]). In glioblastoma (GBM), these can-
cer stem cells were identified a decade
ago (Singh et al., 2004), and their pheno-
typical characterization has since been
refined. It is not definitively clear, howev-
er, whether this ‘‘stemness’’ is intrinsic
to the early tumor cells or is acquired
during tumor development, and the un-
derlying molecular mechanisms behind
this plasticity have also remained largely
obscure.
In this issue of Cell, Suva` et al. (2014)
report on the identification of four tran-
scription factors that can reprogram
differentiated tumor cells into stem-liketumor-propagating cells using combina-
torial mapping of differential epigenetic
marks and gene expression data from
these distinct cell populations.
By culturing freshly harvested GBM
specimens in different conditions (serum
free, spherogenic versus monolayers
with serum), the authors describe two
different cell populations—stem-like tu-
mor-propagating cells (TPCs) and differ-
entiated GBM cells (DGCs), respectively.
TPCs were enriched for postulated stem
cell markers such as CD133 (Singh
et al., 2004) and are tumorigenic in vivo
when as few as 50 cells are transplanted.
Epigenetic profiling for the active en-
hancer mark, H3K27Ac, revealed many
loci that are specific to either TPCs
or DGCs, with enrichment for certain
transcription factor (TF) binding motifs.
Further integration with gene expression
data highlighted 19 development TFs as
being specifically upregulated in TPCs.
Comprehensive combinatorial analysis
of the effects of introducing these factors
in vitro led to the identification of four
core TFs, POU3F2, SALL2, SOX2, and
OLIG2, which are sufficient to reprogram
DGCs into spherogenic, tumorigenic,
induced TPCs (iTPCs; Figure 1). In con-
trast, three-factor combinations were not
able to generate iTPCs. The observed
phenotypic switch was accompanied by
stable epigenetic reprogramming to a
stem-like state, which also led to induc-
tion of expression of the four factors
from endogenous loci.CellAlthough each factor individually was
quite widely expressed in primary tumor
material, coexpression of this quadrumvi-
rate of ‘‘stemness’’ factors was observed
in only 2%–7% of cells. This subset was
also found to be strongly enriched for
CD133 positivity—a marker previously
associated with therapy resistance in a
native tumor setting (Bao et al., 2006).
Whether reprogramming of bulk cells
to a TPC state may also contribute to
chemoresistance and tumor recurrence
is not yet clear.
Finally, by analyzing core nodes in
the transcriptional network controlled by
these factors, the authors highlight a reg-
ulatory role for a chromatin-modifying
complex involving RCOR2 and LSD1.
Treatment with an LSD1 inhibitor spe-
cifically killed TPCs, but not DGCs
or cultured normal astrocytes, whereas
LSD1 knockdown dramatically reduced
the in vivo tumorigenicity of TPCs. The
prospect of targeting both the tumor
bulk and the stem cell compartment may
therefore be one step closer to realization
and could carry the advantage of elimi-
nating tumor-repopulating cells, as well
as potentially blocking dedifferentiation
of DGCs.
The data presented by the authors
offer exciting new insights into tumor
evolutionary hierarchies within GBM
and also lay the foundation for further
investigation into the nature of different
subpopulations. Although this study
does not disprove the differentiation157, April 24, 2014 ª2014 Elsevier Inc. 525
Figure 1. Reprogramming of Differentiated Glioblastoma Cells into Stem-like Tumor-
Propagating Cells with Four Transcription Factors
Four TFs capable of reprogramming DGCs into TPCs were identified using comprehensive epigenetic
mapping and gene expression analysis in glioblastoma cells cultured in serum-containing versus
spherogenic, serum-deprived culture conditions and subsequent integrative analysis. Introduction of
these four TFs into DGCs was sufficient to induce stemness features and tumorigenic potential. Further
investigation of the components downstream of OLIG2 identified LSD1 as a molecular target mediating
the reprogramming that is necessary for TPC survival. Treatment with a specific LSD1 inhibitor reduced
survival and self-renewal of TPCs.model of the cancer stem cell hypothesis,
it suggests that, at least in this experi-
mental system, there is potential for bidi-
rectional plasticity through epigenetic
reprogramming rather than a unidirec-
tional hierarchy between TPCs and
DGCs. Additional molecular analysis of
TPCs extracted from primary material,
through cell sorting for the four TFs, for
example, would be of particular interest
in assessing the wider relevance of this
model. Likewise, assessing the effects
of the iTPC factors on classical long-
term established monolayer cultures
may also provide information as to the
extent of reprogrammability even after
substantial in vitro adaptation.
One further remaining question high-
lighted by the authors is the applicability
of this model and the TPC-inducing fac-
tors across different molecular subtypes
of GBM (Brennan et al., 2013; Sturm
et al., 2014). All of the tumors in the pre-
sent study were of the proneural class,526 Cell 157, April 24, 2014 ª2014 Elsevier Inand it would therefore be of interest to
determinewhether the same or alternative
factors would be sufficient to reprogram
other groups. Of particular interest in this
context is a GBM subtype enriched in
teenagers and young adults, harboring
a G34R/V substitution in histone H3.3.
This group is unusual for GBMs in that it
completely lacks expression of OLIG2
(Sturm et al., 2012), one of the four factors
described by Suva` et al. (2014), suggest-
ing that this is not always essential for
GBM tumorigenesis.
One might also wonder whether the
four iTPC factors influence differentiated
neural cells, and if so, whether a poten-
tially normal stem cell program could be
hijacked in tumor cells. Indeed, other
studies have described tumor induction
through dedifferentiation of neural cells
(Friedmann-Morvinski et al., 2012). In
this context, the question again emerges
as to whether this epigenetic program
is an intrinsic property in a normal cellc.population preceding transforming muta-
tion(s) or whether it can be acquired
stochastically or induced by extrinsic
factors (e.g., mutations or microenviron-
mental cues) over the course of tumor
development.
A link between cancer and normal stem
cells in glioblastoma has previously been
investigated by Stricker et al. (2013). In
that study, the authors applied a subset
of reprogramming factors used in pro-
duction of induced pluripotent stem cells
(iPSCs) (Takahashi and Yamanaka, 2006)
to reprogram genetically aberrant glioma
TPCs. Global DNA methylation patterns
were reset, and the treated cells were
endowed with a capacity to differentiate
into a number of different lineages that
remained capable of inducing tumors
in vivo, suggesting a dominance of onco-
genic alterations over a nonmalignant
epigenetic state in this setting. This tumor-
igenic capacity stands in contrast to the
largely nontumorigenic DGCs of the pre-
sent study; thus, further comparisons
of the properties of these cell states,
the relationship between putative TPC
populations and the multiple genetic
subclones in a given tumor, and the details
of the epigenetic reprogramming induced
by different TF combinations will be of
importance both for our understanding of
phenotypic plasticity in cancer cells and
the interaction between geneticmutations
and the dynamic tumor epigenome.
The cancer stem cell hypothesis has
led to important insights into our under-
standing of tumor evolution and pheno-
typic heterogeneity but also raises many
questions about the dynamics of the
proposed cellular hierarchy as well as
the relationship between tumor-propa-
gating cells and true stem cells. Suva`
et al. (2014) integrate large-scale geno-
mics with substantial functional analysis,
thereby shedding light on differences
between stem-like and differentiated
GBM cells and their interconvertibility,
as well as raising the possibility of novel
targeted therapeutic approaches.REFERENCES
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Tumor suppressors block the development of cancer and are often lost during tumor development.
Papa et al. show that partial loss of normal PTEN tumor suppressor function can be compoundedby
additional disruption caused by the expression of inactivemutant PTENprotein. This has significant
implications for patients with PTEN gene mutations.If half of the cooks in a crowded kitchen
just wander around not doing any work,
the working cooks would almost certainly
work better without them. Similarly, in
biology, there are examples of mutant
proteins that interfere with the function
of their normal functional counterparts
within the same cells. In cancer biology,
perhaps the best recognized example of
this phenomenon is the p53 tumor sup-
pressor, in which partially inactive mutant
proteins aggravate tumor phenotypes
both through interference with normal
p53 when both proteins are present and
also through mechanisms independent
of p53 (Muller and Vousden, 2013). In
this issue of Cell, a new study of another
key tumor-suppressor protein establishes
this paradigm further in cancer biology
(Papa et al., 2014).
An important step in the development
of most cancers is the functional disrup-tion of proteins that have actions that nor-
mally inhibit tumor development, termed
tumor suppressors. PTEN is a tumor
suppressor that is frequently lost, either
partially or fully, from many sporadic
tumor types. A range of mechanisms
causes these losses of function, including
missense and truncation mutations and
deletions in and of the PTEN gene, as
well as reduced expression of active
PTEN mediated by promoter methylation,
the effects of miRNAs, and the suppres-
sion of PTEN enzyme activity (Leslie and
Foti, 2011). Loss of both copies of the
PTEN gene seems to lead to death during
embryonic development, but humans and
other vertebrates can survive carrying one
active and onemutant PTEN gene. Impor-
tantly, PTEN mutation carriers display a
diverse range of pathologies, including tu-
mor susceptibility, developmental abnor-
malities, and autism.The PTEN tumor suppressor appears
to act in a dose-dependent manner, and
in many tumors, loss of function appears
only partial (Alimonti et al., 2010; Carra-
cedo et al., 2011). Accordingly, it is not
uncommon to find evidence that cells
express both normal and inactive mutant
PTEN proteins, both in sporadic tumors
and throughout the body of individuals
who inherit one functional and onemutant
gene. The status of PTEN as a tumor sup-
pressor was established in part through
the study of several lines of transgenic
mice engineered to carry one wild-type
copy of Pten and one null allele that
expresses no active protein. These het-
erozygous mice develop a diverse range
of tumors, with substantial overlap with
the tumor spectrum observed in hu-
man PTEN mutation carriers and often
retaining some normal Pten expression
(Freeman et al., 2006; Knobbe et al.,157, April 24, 2014 ª2014 Elsevier Inc. 527
